[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633166":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":19,"responsibleParty":35,"collaborators":19,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":19,"enrollmentInfo":46,"targetDuration":19,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":61,"whyStopped":19,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":19},{"fullName":5,"class":6},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SINGLE-ARM INTERVENTIONAL STUDY","EXPERIMENTAL","Patients will be seen by the investigator at the radiotherapy clinic on enrolment, at 3 months and at 6 months (the 6-month visit will mark the end of the study)",[13],"Other: Assessment of sexual quality of life",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Assessment of sexual quality of life","The following questionnaires will be completed : EORTC QLQ-SH22 questionnaire, Questionnaire on the impact of HPV infection, HADS questionnaire",[9],null,[21],{"name":22,"affiliation":23,"role":24},"MOUSSION AURORE","DRCI ICM","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"LEMANSKI Claire, study principal investigator","CONTACT","04 67 61 23 91","claire.lemanski@icm.unicancer.fr",{"name":32,"role":28,"phone":33,"phoneExt":19,"email":34},"MORINEAU Louison, intern medecin","07 86 26 63 58","louison.morineau@laposte.net",{"type":36,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100633166","assessment-of-sexual-quality-of-life-following-local-treatment-radiotherapy-with-or-without-surgery-in-patients-with-hpv-positive-pelvic-cancer-a-descriptive-longitudinal-study-100633166",false,"NCT07523152","Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study","SAPPHIRE","Inclusion Criteria:\n\n1. Women aged 18 or over.\n2. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis.\n3. Patients being treated at the Montpellier Cancer Institute (ICM).\n4. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection\n5. Patient aware of her HPV status and how it is transmitted.\n6. Indicated for external radiotherapy\n7. Patient who has not received any oncological treatment prior to inclusion.\n8. Patient who has given verbal consent.\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM).\n2. Patients who are unwilling or unable to complete the study questionnaires.\n3. Patients under guardianship, curatorship or court protection,\n4. Patients for whom regular follow-up is impossible for psychological reasons,\n5. Patients who do not speak French.","FEMALE","18 Years",{"count":47,"type":48},42,"ESTIMATED","INTERVENTIONAL",[51],"NA","In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life.\n\nHowever, few studies have examined the specific effect of HPV status (or knowledge of status) on the recovery\u002Fquality of sexuality following radiotherapy.\n\nIt is against this backdrop that we propose a prospective longitudinal study specifically dedicated to investigating the sexual quality of life of women with HPV-positive pelvic cancer.\n\nThis type of study will enable better quantification and description of sexual dysfunction occurring after treatment, and assessment of the impact of HPV carriage, with the future aim of guiding new prevention and management strategies.",[54,55,56],"Pelvic Cancer","Anal Cancer","Vaginal Cancer",[58,59,60],"vaginal cancer","uterus cancer","anal canal cancer","NOT_YET_RECRUITING","2026-04-04",{"date":64,"type":65},"2026-04-13","ACTUAL",{"date":67,"type":48},"2026-04-02",{"date":69,"type":48},"2027-10-31",{"name":5,"class":6}]